Turn Therapeutics Q2 net loss per share widens on higher R&D costs
TTRX•Outlook
- The company expects to complete GX-03 Phase 2 enrollment by the end of 2026.
- Turn targets first patient dosing in a hidradenitis suppurativa study for Q2 2027.
- The company expects cash to fund operations into Q3 2027.
Result drivers and key details
- R&D spending increased, driven by expanded Phase 2 trial activity for GX-03.
- The company expanded the GX-03 Phase 2 study after interim analysis showed efficacy in a broader atopic dermatitis patient group.
| Metric | Beat/Miss | Actual | Consensus Estimate |
|---|---|---|---|
| Q2 Loss Per Share | $0.20 |
Q2 net loss widens as R&D spending rises
- US biotechnology firm's Q2 net loss per share widened year over year as R&D expenses increased.
- The company expanded its GX-03 Phase 2 study after an interim analysis showed efficacy in a broader patient group.
- Former FDA Commissioner Dr. Stephen Hahn was appointed Executive Clinical and Regulatory Lead during Q2.
